Bill shields formula makers from state courts, harming injured families
S. 4940 — Specialized Infant Formula Protection Act · Filed by Joni Ernst (R-IA) · Introduced Jun 24, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill moves all lawsuits over preterm infant formula injuries from state courts to federal courts, and allows any defendant to move a case to federal court without all defendants agreeing. The stated purpose is to prevent 'court shopping' and ensure uniform legal remedies, protecting the supply of specialized formula for premature babies.
Why we flagged it
The bill's operative mechanism is a jurisdictional carve-out that strips state courts of authority over formula injury claims and enables unilateral removal to federal court. While framed as supply protection, the functional effect is to shield defendants (formula manufacturers) from state-court litigation and class actions, which are historically more plaintiff-friendly.
What the text implies
- Federal courts apply stricter pleading standards (Rule 11, Twombly/Iqbal) and are generally more hostile to class certification than state courts, reducing injured families' ability to aggregate claims and recover damages.
- Removal without consent of all defendants allows manufacturers to forum-shift unilaterally, eliminating plaintiffs' choice of venue and forcing them into federal dockets where they face higher barriers to entry and discovery.
The full analysis lists 4 implications of this text.
Who stands to gain
infant formula manufacturers (Bristol Myers Squibb, Gerber/Nestlé, Pfizer, Johnson & Johnson); pharmaceutical and medical device companies with similar litigation exposure